Sign up
Pharma Capital

Alliance Pharma reports strong growth as it launches UK's first prescribed drug for morning sickness

Peter Butterfield, chief executive of Alliance Pharma plc (LON:APH), updates Proactive's Andrew Scott on the group's first half performance.

A strong performance from its portfolio of international brands boosted first-half sales.

Turnover rose by 10% to £54.5m (2017: £49.4m) with scar tissue treatment Kelo-cote seeing sales rise by 77% while eye supplement Macushield was 22% ahead of a year ago.

Since June they've also launched the UK’s only prescription treatment for vomiting and nausea during pregnancy.

Sold under the brand name Xonvea, Diclectin was licensed from Duchesnay of Canada in 2015 and has been prescribed to 33mln women over 40 years.

 

View full APH profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.